The financing news reported by the Venture Capital Channel and the early entrepreneurial projects in various fields we are focusing on.
Please check the Venture Capital Daily on August 23. The Venture Capital Daily includes the financing news reported by today’s “Venture Channel” and the early entrepreneurial projects in various fields we are focusing on, enjoy~
Financing News Report
Starting | Baidu, Shenzhen Venture Capital, Qianhaimu Fund betting small class, “Junior English” completed hundreds of millions of C1 rounds of financing
Starting | Cross-border Commodity Integrated Services Platform “Cloud Global Remittance” completed $100 million B+ round Financing, focus on the offline store
Starting|Building a cat “popular brand” around the highest LTV female users, “FURRYTAIL tail life” Received 80 million A rounds and A+ round financing
Early Project Report
Looking at the trillion blue ocean market, “home online” wants to be self-built Room version of the Tuban rabbit”
潮科技新风向
Chao Technology | Cell Therapy Industry Exploration: CAPRI Cell Therapy
Introduction to Early Projects (Stem Cell and Regenerative Medicine)
Project Name: Boya Stem Cell
In one sentence: stem cells and regenerative medicine
Boya Stem Cell was established in 2009. Currently, it is mainly engaged in stem cell storage business. It not only has patented cell processing and storage technology, but also cooperates with more than 40 top three hospitals nationwide to promote stem cell clinical research and application. The company has Wuxi, Beijing, Tianjin and Chongqing in the country.The five stem cell banks in Guangdong cover most provinces and cities. Boya Stem Cell is a subsidiary of Boya Holding Group. The group has technology research and development in the downstream of stem cells. Autologous stem cell technology has been approved for the third phase of clinical approval of the US FDA for the treatment of severe limb ischemia (CLI). Stem cell clinical projects and cell therapy have been marketed. According to public information, Boya Stem Cell completed the A round of financing in 2015, and the investor is Xinri Hengli. The founder of the company, Xu Xiaotong, is a Ph.D. in immunology at the University of Washington School of Medicine and a visiting professor at the Institute of Molecular Medicine at Peking University. (Author: dreamer Cai Cai)
Project Name: Shengyu Bio
In one sentence: stem cells and regenerative medicine
Shenzhen Shengyu is mainly engaged in research on regenerative medicine engineering technology, mainly doing autologous stem cell anti-aging technology and corresponding anti-aging treatment services. Shenzhen Shengyu is a team of scientists and entrepreneurs. It has undertaken a number of major stem cell project projects in various countries. It has completed the development of the relevant autologous stem cell anti-aging clinical treatment technology and the construction of stem cell banks. Dr. Xu Wei, the company’s chief stem cell expert, is a visiting professor at Ohio State University and was awarded a special prize by the American Academy of Dermatology Research in 2014. The sales and service model uses a membership system to provide members with anti-aging technology and expert resources. (Author: dreamer Cai Cai)
Project Name: Fanmei International
In one sentence: stem cells and regenerative medicine
Vanmei International specializes in regenerative medicine, and uses stem cell clinical transformation as a technology to carry out clinical transformation applications in stem cell and regenerative medicine research, precision medicine, genetic testing, etc., and provides a “cell factory” full industrial chain service. The company has autonomous research institutes and professional teams, providing professional customization, personal personalized services, and mastering cell resuscitation techniques and cell storage technologies. Its research institute has laboratories built to GMP standards, and 95% of its equipment comes from the latest series of products from THERMO FISHER. (Author: dreamer Cai Cai)
Project Name: Wanhai Cell
In one sentence: stem cells and regenerative medicine
Guangdong Wanhai Cell Biotechnology has independently developed all-in-one Car-T technology in the fields of stem cell medical beauty, cell banking, cell therapy research, tissue regeneration engineering, etc., and has obtained dozens of national invention patents. The company has established cell centers and R&D production bases in Dongguan, Shenzhen, Wuhan, Zhengzhou and other cities, and built laboratories that meet GMP standards, and many international medical colleges and more than ten stem cell engineering centers nationwide.